- Reported transaction lines
- 1
- Buy lines
- 1
- Sell lines
- 0
Filing activity by month
Original filing lines in up to 12 months with activity.
- 2026-111
Frequently disclosed stocks
Disclosure history
| Reporting investor | Security | Activity | Transaction / period | Filed | Reported amount | Source |
|---|---|---|---|---|---|---|
| Mulroy Michael H. Director · Lineage Cell Therapeutics, Inc. | LCTX Lineage Cell Therapeutics, Inc. | BuyFiling detailsSEC transaction code P Common Shares · Direct ownership · Reported balance after transaction: 328555 · SEC code covers open-market or private transactions · The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.8656 to $0.8755 inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within theranges set forth in this footnote 1. | 2026-11-17 | 2026-11-19 | ≈ $26,100.00 30,000 shares/units | SEC 4 |
Counts describe original filing lines in BriefStock’s coverage. Later amendments can correct or supplement them. Check the original filing for ownership and transaction details.